《Bora Pharmaceuticals_2026 44th JPM conference_CH.pdf》由会员分享,可在线阅读,更多相关《Bora Pharmaceuticals_2026 44th JPM conference_CH.pdf(28页珍藏版)》请在三个皮匠报告上搜索。
1、Make Success More CertainJP Morgan Healthcare Conference 2026Except for historical information contained herein,the matters set forth in this presentation are forward looking statements thatare subject to risks and uncertainties that could cause actual results to differ materially.These forward-look
2、ing statements are not based on historical facts but rather on managements expectations regarding futuregrowth,results of operations,performance,future capital and other expenditures,competitive advantages,business prospectsand opportunities.Statements in this presentation about our future plans and
3、 intentions,results,level of activities,performance,goals or achievements or other future events constitute forward looking statements.Wherever possible,words such as“anticipate”,“believe”,“expect”,“may”,“could”,“will”,“potential”,“intend”,“estimate”,“should”,“plan”,“predict”,or the negativeor other
4、 variations of statements reflect managements current beliefs and assumptions and are based on the informationcurrently available to our management.Investors are cautioned not to place undue reliance on these forward-looking statements,which are made as of the date ofthis presentation,and we assume
5、no obligation to update or revise any forward-looking statements.2DisclaimerBora by the Numbers*As o Dec 2025 2.0+Billion USD市值*2100+員工人數100+出口國家10CDMO廠區634 Million USD2025 年營收95%營收來自海外#1台灣製藥公司320252024保瑞發展里程碑保瑞藥業成立併購衛采(Eisai)台南廠上櫃並收購台灣宇泰欣藥收購加拿大廠(前為 GSK)收購保盛藥業(前為安成藥業)於臺灣證券交易所上市完成對美國馬里蘭針劑廠(前 Emergent
6、)的併購進一步擴展小分子 CDMO 業務,收購益邦竹南廠(前為 Impax/Amneal),加速進入美國市場成立保瑞生技並收購伊甸生醫,正式跨足大分子藥物投資晨暉生技,成為最大股東完成對 Upsher-Smith的併購完成對專注於生物製劑藥物委託開發暨製造服務(CDMO)與生物相似藥開發的泰福生技股份有限公司的策略結盟202420242023202320222022202020182017201320074收購美國 Pyros Pharmaceuticals取得小兒神經罕見疾病領先品牌與重點客戶成功續約數年量產合約史上最大規模資本支出與行銷資源投入CDMO業務,而自由現金流仍持續擴張完成泰福生